Rosen A C, Goh C, Lacouture M E, Mehrara B J, Cordeiro P G, Myskowski P L
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 NW 10th Ave, RMSB 2023A, Miami, FL 33139, USA.
Department of Medicine, Dermatology Division, David Geffen School of Medicine at UCLA, UCLA Dermatology Center, Peter Morton Medical Building, 200 UCLA Medical Plaza, Ste 465, Los Angeles, CA 90095, USA.
J Plast Reconstr Aesthet Surg. 2017 Oct;70(10):1369-1376. doi: 10.1016/j.bjps.2017.05.012. Epub 2017 May 20.
Approximately one-third of women diagnosed with breast cancer undergo mastectomy with subsequent implant-based or autogenous tissue-based reconstruction. Potential complications include infection, capsular contracture, and leak or rupture of implants with necessity for explantation. Skin rashes are infrequently described complications of patients who undergo mastectomy with or without reconstruction.
A retrospective analysis of breast cancer patients referred to the Dermatology Service for diagnosis and management of a rash post-mastectomy and expander or implant placement or transverse rectus abdominis myocutaneous (TRAM) flap reconstruction was performed. Parameters studied included reconstruction types, time to onset, clinical presentation, associated symptoms, results of microbiologic studies, management, and outcome.
We describe 21 patients who developed a rash on the skin overlying a breast reconstruction. Average time to onset was 25.7 months after expander placement or TRAM flap reconstruction. Clinical presentations included macules and papules or scaly, erythematous patches and plaques. Five patients had cultures of the rash, which were all negative. Skin biopsy was relatively contraindicated in areas of skin tension, and was reserved for non-responding eruptions. Treatments included topical corticosteroids and topical antibiotics, which resulted in complete or partial responses in all patients with documented follow-ups.
Our findings suggest that tension and post-surgical factors play a causal role in this hitherto undescribed entity: "post-reconstruction dermatitis of the breast." This is a manageable condition that develops weeks to years following breast reconstruction. Topical corticosteroids and antibiotics result in restoration of skin barrier integrity and decreased secondary infection.
约三分之一被诊断为乳腺癌的女性会接受乳房切除术,随后进行基于植入物或自体组织的重建手术。潜在并发症包括感染、包膜挛缩以及植入物渗漏或破裂并需要取出。皮疹是接受或未接受重建手术的乳房切除患者中较少被描述的并发症。
对转诊至皮肤科进行乳房切除术后皮疹诊断和处理以及扩张器或植入物置入或腹直肌肌皮瓣(TRAM)重建的乳腺癌患者进行回顾性分析。研究参数包括重建类型、发病时间、临床表现、相关症状、微生物学研究结果、处理方法和结局。
我们描述了21例在乳房重建上方皮肤出现皮疹的患者。扩张器置入或TRAM皮瓣重建后皮疹平均发病时间为25.7个月。临床表现包括斑疹、丘疹或鳞屑性红斑斑块。5例患者对皮疹进行了培养,结果均为阴性。在皮肤张力较大的区域相对禁忌进行皮肤活检,仅用于对治疗无反应的皮疹。治疗方法包括外用糖皮质激素和外用抗生素,所有有记录随访的患者均有完全或部分缓解。
我们的研究结果表明,张力和术后因素在这种此前未被描述的病症“乳房重建后皮炎”中起因果作用。这是一种在乳房重建后数周数年发生的可控制病症。外用糖皮质激素和抗生素可恢复皮肤屏障完整性并减少继发感染。